Juva Life Inc. (JUVAF)
| Market Cap | 164.00 |
| Revenue (ttm) | 7.93M +43.0% |
| Net Income | -6.81M |
| EPS | -0.04 |
| Shares Out | 164.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | -7.73 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Juva Life
Juva Life Inc. acquires, owns, and operates in cannabis business in medical and recreational cannabis sectors in California, the United States. The company operates through two segments, The Resale of Merchandise and Cannabis-Derived Products and Cultivation and Sale of Trim and Flowers. Juva Life Inc. was founded in 2018 and is based in Vancouver, Canada. [Read more]
Full Company ProfileNews
Juva Life Inc. Updates Shareholders on Court-Appointed Receivership Proceedings
REDWOOD CITY, CA / ACCESSWIRE / November 25, 2024 / Juva Life Inc. (CSE:JUVA)(OTC PINK:JUVAF)(FRANKFURT:4VV) ("Juva" or the "Company"), a life science company with both pharmaceutical research and dev...
Juva Life Inc. Updates Shareholders on Financial Status and Upcoming Receivership Hearing
REDWOOD CITY, CA / ACCESSWIRE / November 5, 2024 / Juva Life Inc. (CSE:JUVA)(OTC EXPERT MARKET:JUVAF)(FRANKFURT:4VV) ("Juva" or the "Company"), a life science company with both pharmaceutical research...
Juva Life Unveils New Cannabis Vape Category - Rosin Absolute - Introduces Infused Flower Offerings and Announces Partnership With Cloudius9
REDWOOD CITY, CA / ACCESSWIRE / April 16, 2024 / Juva Life Inc. (CSE:JUVA)(OTCQB:JUVAF)(FRANKFURT:4VV) ("Juva Life" or the "Company"), Juva Life Inc, a life science company with both pharmaceutical re...
Juva Life Reports Strong Growth in Q3 2023 Financial Results
REDWOOD CITY, CA / ACCESSWIRE / December 13, 2023 / Juva Life Inc. (CSE:JUVA)(OTCQB:JUVAF)(FRANKFURT:4VV) ("Juva Life" or the "Company"), Juva Life, Inc, a life science company with both pharmaceutica...
Juva Life Begins Construction on Redwood City Retail Storefront, On Track to Open in Early 2023
Company Was Previously the Highest-Scoring Applicant During the Permitting Process in Redwood City, California Company Was Previously the Highest-Scoring Applicant During the Permitting Process in Red...
Juva Life Successfully Scales Novel Compound JUVA-041 for Preclinical Studies and Eventual Commercialization, Highlighting Successful Chemistry Process
Company Reports Successful Medicinal Chemistry Effort to Scale Up Small Molecule Isolated from Cannabis Plant to Support Preclinical and Non-Clinical Studies Company Reports Successful Medicinal Chemi...
Juva Life Announces Flōs, New Branded Cannabis Flower Product Line
New Branded Cannabis Product Line Diversifies Company Product Offerings; Compliments Pharmaceutical Research New Branded Cannabis Product Line Diversifies Company Product Offerings; Compliments Pharma...
Juva Life Reports 144% Increase in Revenue for Q2 2022; Schedules Webinar for 9/6/22
Company Reports Its Q2 2022 Financial Results and Provides Comments on Operations Company Reports Its Q2 2022 Financial Results and Provides Comments on Operations
Juva Life Launches Revised JuLi Registry, Showcases Cannabis and CBD Brands to Track Effects on Cannabis Patients
Life Science Research and Vertically Integrated California Cultivator Creates Global Research Registry to Better Understand Clinical Effects of Cannabis
Juva Life Highlights Q1 2022 Financials Showing 97% Increase in Revenue
Company Reports Its Q1 2022 Results and Provides Comments on Operations Company Reports Its Q1 2022 Results and Provides Comments on Operations
Juva Life Secures $11.8 Million in Financing, Enabling Expansion of Cannabis Operations, Further Clinical Research
Cannabis and Life Sciences Company Closes $11.8 Million in Non-Dilutive Debt Financing Cannabis and Life Sciences Company Closes $11.8 Million in Non-Dilutive Debt Financing
Juva Life Granted First-of-Its-Kind License for Retail Cannabis Storefront in Redwood City, California
In Highly Competitive Process, Vertically Integrated California Cultivator and Life Science Research Company Approved to Launch Brick-and-Mortar Location In Highly Competitive Process, Vertically Inte...
Juva Life Launches First In-House Branded Product: ‘Secret Sauce' Concentrate – in Response to Market Segment Growth
Vertically Integrated California Cultivator and Life Science Research Company Expands Strategically Into New Category Vertically Integrated California Cultivator and Life Science Research Company Expa...
Juva Life Announces Webinar Takeaways, Showcasing Increased Production Output, Operational Milestones and Pharmaceutical Advancements
Cannabis and Life Sciences Company Webinar Highlights Milestones, Growth and Future Plans Cannabis and Life Sciences Company Webinar Highlights Milestones, Growth and Future Plans
Juva Life Announces Completion of Stockton, California, Cannabis Cultivation Facility, Doubling Harvest Capacity
Cannabis and Life Sciences Company Doubles Capacity of Stockton Cultivation Facility With Completed Construction Cannabis and Life Sciences Company Doubles Capacity of Stockton Cultivation Facility Wi...
Juva Life Launches Journal App, Offering Personal Health and Wellness Tracking for Cannabis Patients
Life Science Research & Vertically Integrated California Cultivator Offers App to Help Consumers Track Cannabis Effects on Their Health and Wellness Life Science Research & Vertically Integrated Calif...
Juva Life Announces Filing of Patent on JUVA-041 – Small Molecule Isolated from the Cannabis Plant
Potent Anti-Inflammatory Non-Cannabinoid Molecule Potent Anti-Inflammatory Non-Cannabinoid Molecule
Juva Life Validates Discovery Strategy and Technology Platform, Leading to Discovery of Second Novel Drug Candidate, JUVA-041 Nominated for Pre-Clinical Development
Methodical, Efficient Approach to Drug Discovery Advances Non-Cannabinoid Molecule as Unique Development Candidate Methodical, Efficient Approach to Drug Discovery Advances Non-Cannabinoid Molecule as...
Juva Life Advances JUVA-019 into Preclinical Development for Inflammatory Disease
JUVA-019 Observed Potency Leads to Advancement Along Drug Development Pathway JUVA-019 Observed Potency Leads to Advancement Along Drug Development Pathway
Juva Life Expands WIRB-Approved Cannabis Patient Registry Study
Company launches first U.S wide cannabis registry for Critical Research on How Cannabis Can Improve Public Health Company launches first U.S wide cannabis registry for Critical Research on How Cannabi...
Juva Life Reports 322% Increase in Revenue in 2021 Third Quarter Financial and Operational Results Filing
Cannabis and Life Sciences Company Reports Q3 Results and Provides Comment on Operations Cannabis and Life Sciences Company Reports Q3 Results and Provides Comment on Operations
Juva Life Launches Preclinical Comparative Study to Evaluate Anti-Inflammatory Properties of Candidate JUVA-019 in Conjunction With Other Well-Known Cannabinoids
Cannabis and Life Sciences Company Initiates Internal Study Comparing Anti-Inflammatory Properties of Candidate JUVA-019 When Combined With Cannabinoids Such as THC and CBD Cannabis and Life Sciences ...
Juva Life Identifies Second Molecular Compound Found in Cannabis With Significant Anti-Inflammatory Therapeutic Properties Coined JUVA-041
Cannabis and Life Sciences Company Adds Second Novel Non-Cannabinoid Compound to Pharmaceutical Pipeline Cannabis and Life Sciences Company Adds Second Novel Non-Cannabinoid Compound to Pharmaceutical...
Juva Life Files Patent on Family of Non-Cannabinoid Small Molecules Targeting Consumer and Pharma Inflammatory Indications
VANCOUVER, British Columbia, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California based life sciences compa...
Juva Life Announces Top Line R/D Data and Initiates Optimization & Development of Juva-019
--Company identifies Non-Cannabinoid Anti-Inflammatory Compounds Suitable for Drug and Consumer Product Development --Company identifies Non-Cannabinoid Anti-Inflammatory Compounds Suitable for Drug a...